Sangamo Therapeutics, Inc. (SGMO)

Sangamo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	41.92	45.2	100.44	178.87	131.33
Short-Term Investments	-	35.8	177.19	197.68	510.09
Cash & Short-Term Investments	41.92	81	277.63	376.55	641.42
Cash Growth	-48.25%	-70.82%	-26.27%	-41.30%	76.96%
Accounts Receivable	0.53	0.92	3.68	6.01	5.22
Other Receivables	4.07	3.14	0.79	0.35	1.04
Receivables	4.6	4.07	4.47	6.36	6.26
Prepaid Expenses	5.18	9.26	18.22	15.86	11.99
Total Current Assets	51.69	94.33	300.33	398.77	659.67
Property, Plant & Equipment	34.76	52.87	125.53	124.7	112.37
Long-Term Investments	-	-	29.85	88.17	50.53
Goodwill	-	-	37.55	39.7	42.8
Other Intangible Assets	-	-	50.73	53.76	58.13
Long-Term Deferred Tax Assets	-	-	1.12	1.06	0.47
Other Long-Term Assets	15.19	18.13	17.41	15.76	14.58
Total Assets	101.64	165.32	562.51	721.92	938.55
Accounts Payable	15.49	15.26	22.42	9.76	12.55
Accrued Expenses	17.56	16.15	33.39	28.39	30.66
Current Portion of Leases	4.31	4.59	4.12	4.03	3.69
Current Unearned Revenue	7.56	-	51.78	85.71	91.64
Other Current Liabilities	0.9	11.73	-	-	5
Total Current Liabilities	45.81	47.73	111.71	127.89	143.55
Long-Term Leases	26.25	33.52	38.99	44.06	38.4
Long-Term Unearned Revenue	5.87	-	109.38	166.78	245.05
Long-Term Deferred Tax Liabilities	-	-	6.27	6.65	7.19
Other Long-Term Liabilities	0.93	1.19	1.21	1.22	7.01
Total Liabilities	78.87	82.43	267.55	346.58	441.18
Common Stock	2.13	1.78	1.67	1.46	1.42
Additional Paid-In Capital	1,532	1,492	1,450	1,334	1,269
Retained Earnings	-1,504	-1,406	-1,149	-956.27	-777.98
Comprehensive Income & Other	-7.53	-4.6	-8.4	-3.99	5.42
Total Common Equity	22.77	82.89	294.96	375.34	498.23
Minority Interest	-	-	-	-	-0.87
Shareholders' Equity	22.77	82.89	294.96	375.34	497.37
Total Liabilities & Equity	101.64	165.32	562.51	721.92	938.55
Total Debt	30.57	38.1	43.11	48.08	42.09
Net Cash (Debt)	11.35	42.9	264.37	416.64	649.87
Net Cash Growth	-73.54%	-83.77%	-36.55%	-35.89%	91.19%
Net Cash Per Share	0.06	0.25	1.71	2.88	4.83
Filing Date Shares Outstanding	224.71	178.91	168.48	145.97	143.25
Total Common Shares Outstanding	212.84	178.13	166.79	145.92	142.06
Working Capital	5.89	46.6	188.62	270.88	516.12
Book Value Per Share	0.11	0.47	1.77	2.57	3.51
Tangible Book Value	22.77	82.89	206.68	281.88	397.31
Tangible Book Value Per Share	0.11	0.47	1.24	1.93	2.80
Machinery	32.78	47.02	54.72	49.85	30.7
Construction In Progress	-	1.09	14.77	4.73	12.09
Leasehold Improvements	24.92	29.81	30.57	21.97	15.95

Updated Mar 17, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q